Contineum Therapeutics (CTNM) Expected to Announce Quarterly Earnings on Wednesday

Contineum Therapeutics (NASDAQ:CTNM) is projected to post its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect Contineum Therapeutics to post earnings of ($0.55) per share for the quarter. Individuals can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 4:00 PM ET.

Contineum Therapeutics (NASDAQ:CTNM) last issued its earnings results on Tuesday, May 5th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.16. On average, analysts expect Contineum Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Contineum Therapeutics Price Performance

Shares of CTNM stock opened at $13.65 on Tuesday. The firm’s 50-day moving average is $13.35 and its two-hundred day moving average is $12.63. Contineum Therapeutics has a 12 month low of $3.35 and a 12 month high of $16.33. The company has a market capitalization of $510.37 million, a PE ratio of -7.00 and a beta of 0.89.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Contineum Therapeutics in a report on Monday, April 20th. Wall Street Zen upgraded Contineum Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Robert W. Baird upped their price objective on Contineum Therapeutics from $14.00 to $20.00 and gave the company an “outperform” rating in a report on Friday, March 6th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Contineum Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $19.50.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Ikarian Capital LLC purchased a new position in shares of Contineum Therapeutics in the fourth quarter valued at approximately $3,233,000. Sphera Funds Management LTD. purchased a new position in shares of Contineum Therapeutics in the fourth quarter valued at approximately $1,983,000. Suvretta Capital Management LLC boosted its stake in shares of Contineum Therapeutics by 65.2% in the fourth quarter. Suvretta Capital Management LLC now owns 2,841,334 shares of the company’s stock valued at $32,476,000 after purchasing an additional 1,121,334 shares during the period. Quadrature Capital Ltd acquired a new position in shares of Contineum Therapeutics in the fourth quarter worth $267,000. Finally, Occudo Quantitative Strategies LP acquired a new position in shares of Contineum Therapeutics in the fourth quarter worth $172,000.

About Contineum Therapeutics

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.